Early Signs of Dementia: How Advanced Testing at PICMI Can Protect Your Brain

Dementia doesn’t begin with a diagnosis—it begins quietly. Long before memory loss disrupts daily life, the brain may already be under stress, adapting, and compensating in ways that go unnoticed. Occasional forgetfulness is normal, but repeated lapses, difficulty planning, trouble finding words, or unexplained shifts in mood can signal deeper changes taking place beneath the surface.

The challenge is that by the time these signals become obvious, valuable time for prevention is often lost. Pinpointing risk ahead of time creates the opportunity to protect memory, preserve independence, and adjust the trajectory of brain aging.

These often invisible signs can only be identified through advanced diagnostics designed to detect brain risk before symptoms emerge.

Advanced Diagnostics That Make Early Detection Possible

Genomic Testing

Your genes influence memory, focus, and cognitive resilience over time. PICMI’s genomic testing reveals biological patterns that may contribute to cognitive decline, including:

• Neurotransmitter pathways affecting memory and mood
• Hormone-related vulnerabilities that impact cognition
• Inflammatory, detoxification, and nutrient pathways linked to brain health

Identifying these factors upstream allows us to design personalized strategies that support long-term brain function and resilience.

Brain Mapping (EEG + 3D Imaging)

Our clinical brain mapping evaluates real-time brain network activity, revealing changes in memory, attention, and executive function. This functional insight goes beyond performance-based testing, helping us understand how your brain is communicating, adapting, and compensating—so interventions can be precisely targeted.

Advanced Blood-Based Diagnostics

Standard laboratory testing is designed to detect disease after symptoms emerge. At PICMI, advanced blood-based diagnostics are used to uncover biological signals of brain stress and neurodegeneration—up to a decade before cognitive symptoms develop.

In addition to assessing hormone balance, inflammation, metabolic efficiency, and cellular health, we evaluate highly sensitive neurological biomarkers that provide direct insight into brain integrity. These biomarkers include:

• U-p217: A highly specific biomarker associated with Alzheimer-related processes. Elevated levels may signal pathological changes long before clinical symptoms appear, making it valuable for risk identification, monitoring progression, and tracking response to intervention.
• Neurofilament Light (NfL): A marker of active brain cell injury. NfL helps determine whether ongoing neuronal damage is occurring due to vascular disease, prior head trauma, or neurodegenerative processes—often before changes are visible on imaging or cognitive testing.
• Glial Fibrillary Acidic Protein (GFAP): A marker of brain inflammation and repair activity. Elevated GFAP levels indicate ongoing inflammatory stress within the brain and provide insight into neuroinflammatory processes that contribute to cognitive decline.

Together, these biomarkers allow us to detect subtle neurological stress early, differentiate contributing pathways, and take action before irreversible damage occurs.

Protect Your Brain Today

Through genomic testing, advanced brain mapping, and precision blood-based diagnostics, PICMI designs individualized care plans focused on proactive brain health and risk identification.

By catching changes early and addressing their biological drivers, you gain the opportunity to protect clarity, independence, and quality of life—before decline takes hold.